This week in health news, activist investor Engine Capital urges Avantor's board overhaul, China's Ab&B Bio-Tech IPO sees ...

Shares of IO Biotech fell after the company said a cancer vaccine narrowly missed statistical significance on a Phase 3 study's primary endpoint. The stock was down 36%, to $1.15, late Monday ...

Cylembio did not meet its primary endpoint of progression-free survival (PFS), but did demonstrate a trend towards ...

Slovenská sporiteľňa has appointed Michaela Bauer as its next CEO, effective 1 March 2026, pending regulatory approval. Bauer brings over two ...

A regimen involving the company’s shot failed a Phase 3 trial “by a hair,” an executive said, leading the company to believe ...

TUM student teams have taken first and second place at the EuroTeQaThon 2025 in Eindhoven for innovative projects addressing global and local cha ...

IO Biotech said on Monday its experimental combination vaccine for a type of skin cancer helped slow the disease's ...

Denmark-based IO Biotech’s shares traded 51% higher ahead of the morning bell at $2.74 after the company said that Cylembio ...

IO Biotech (IOBT) announced on Monday that its investigational and therapeutic cancer vaccine, Cylembio, in combination with ...

IO Biotech reported its phase 3 trial readout on melanoma immunotherapy. Check out my updated investment thesis on IOBT stock ...

IO Biotech's Phase 3 trial showed Cylembio plus Keytruda improved progression-free survival in advanced melanoma across most ...

IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma ...